Merck Serono to Collaborate With The Institute of Cancer Research, London, and Wellcome Trust
Joint program to develop drug candidates for the treatment of different forms of cancer
08-Oct-2014 -
Merck Serono, the biopharmaceutical division of Merck, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an ...
cancer
drug discovery
Merck
+1